Crawford FDA Confirmation Vote Expected By Mid-May
This article was originally published in The Pink Sheet Daily
Executive Summary
The vote would come just over a month after an April 13 Senate Health Committee vote on Crawford's nomination for FDA commissioner was abruptly cancelled. Barr expects FDA approval of its Rx-to-OTC switch application for Plan B once a permanent commissioner is in place.
You may also be interested in...
Plan B Headed For Behind-The-Counter Sale
FDA is understood to have decided to approve the emergency contraceptive as a new, third class of product, which would restrict access but not require a prescription.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.
An Artificial Intelligence Milestone For US FDA
A project to validate a depression severity measurement tool that employs artificial intelligence for use in drug trials is moving forward at FDA. The milestone is a sign of things to come – and of the incremental process for AI adoption by the regulator.